Are you still enduring recurrent migraine ? Or is it a severe headache while resisting painkillers? The days of dying pain are about to end. The innovative migraine drug irinaezumab was unveiled at the 5th CIIE, which is expected to fill the gap in the "no new drugs available" for migraine patients in China and provide a new preventive treatment plan for migraine patients in China.
Migraine is a common chronic neurovascular disease, mainly manifested as repeated severe headaches, and may also be combined with symptoms of neurological dysfunction such as nausea, vomiting, photophobia and vocal fear. There are many patients with migraine. epidemiological survey shows that the prevalence of migraine among people aged 18 to 65 is 9.3%, among which women are more common. Repeated severe headaches will not only seriously affect the patient's life and work, but also make migraine patients more likely to be associated with other diseases, such as anxiety and depression, as well as leukocerebral lesions, ischemic stroke, and other diseases.
At present, the treatment of migraine is mainly based on acute pain relief and remission prevention. However, in order to quickly relieve pain, many migraine patients often rely solely on pain medication. Handler Li Yansheng, Department of Neurology Affiliated to the School of Medicine of Shanghai Jiaotong University, pointed out that from the large number of clinical migraine cases, long-term and large-scale use of painkillers will not only lead to severe gastrointestinal reactions, but also damage renal function. Taking painkillers continuously for 3 months and taking them for more than 10 days per month may cause excessive medication headaches. Preventive drugs used for migraine, including antidepressant, anti-anxiety, anti-epileptics, and ion channel blockers, not only have limited treatment effects but also have obvious adverse reactions.
Latest research found that CGRP (calcitonin gene-related peptide) plays a key role in migraine pathophysiology. Professor Li Yansheng explained that when migraine occurs, CGRP levels in cerebrospinal fluid , saliva and plasma are elevated, and during this period, the release of CGRP stimulated the trigeminal neural pathway increases. Blocking CGRP or its receptors can control acute migraine or prevent migraine attacks. Erenaizumab is the world's first and only innovative migraine drug targeting CGRP receptors, which can effectively block the interaction between CGRP and CGRP receptors.
Hyper Department of Neurology, Sun Yat-sen University Sun Yixian Memorial Hospital, said that irina yuzumab only needs to be injected once a month, which can effectively reduce the number of days of migraine after 1 week of treatment and is relatively convenient to use. Clinical studies showed that during the 5-year follow-up, 71% of patients reduced their monthly migraine days by more than half after use, 36% had no attacks at all, the average monthly attack days decreased by 7 days, and were well tolerated, and the incidence of total adverse events in was similar to that in the placebo group. The implementation of the
" Hong Kong and Macau Pharmaceutical and Devices Connect " policy provides another channel for overseas innovative drugs to benefit Chinese patients. Irenaizumab has been launched in , the Greater Bay Area of , one of the 45 innovative drugs of Novartis, and has provided help to many patients suffering from migraine.
(Pan Jiayi)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-